Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Type, By Technology, By Offering, By Application, By End User, By Region & Competition, 2021-2031F

The Global market for flow cytometry in oncology and immunology is anticipated to expand from USD 3.63 billion in 2025 to USD 5.84 billion by 2031, reflecting a compound annual growth rate of 8.25%. This technology serves as an essential laboratory technique for the swift, multiparametric evaluation of cell populations, utilizing fluorescent and light-scattering properties to define cellular functions, states, and types. It plays a vital role in diagnosing diseases, determining prognoses, and monitoring therapies in these specialized medical domains. Market expansion is largely fueled by the rising worldwide prevalence of cancer and immunological conditions, which drives the need for sophisticated research and diagnostic instruments. Additionally, increasing investments in research and development for biomarker identification and personalized medicine, coupled with ongoing technological upgrades to instrument capabilities, strongly boost market demand. Highlighting the robust interest in this sector, the International Society for Advancement of Cytometry reported that its CYTO 2025 annual congress hosted over 1,600 attendees from more than 40 nations.

A major obstacle hindering the growth of this market is the heavy capital investment needed to procure cutting-edge flow cytometry equipment and the related reagents. Such steep upfront costs can limit the uptake of this technology, especially among smaller labs and healthcare facilities in developing areas. Furthermore, the requirement for extensively trained professionals to manage these complex systems and accurately interpret the resulting data poses a continuous operational challenge to widespread adoption.

Market Driver

The Global flow cytometry market is heavily propelled by its broadening uses in cancer diagnostics and research. As novel treatment approaches emerge, this technology has become essential for detailing cancer cell characteristics, tracking disease advancement, and assessing therapeutic efficacy. The growing intricacies of oncology necessitate advanced instruments for personalized medicine and identifying biomarkers, positioning flow cytometry as a core element in clinical and research environments alike. Illustrating this trend, the American Association for Cancer Research (AACR) Cancer Progress Report 2025 noted that between July 1, 2024, and June 30, 2025, the FDA cleared 20 novel anticancer drugs, new applications for eight existing cancer therapies, and two fresh early detection instruments. This surge in cleared diagnostics and treatments directly boosts the need for flow cytometry to assist in their creation and application.

At the same time, continuous technological progress in flow cytometry systems serves as a major growth engine, expanding the limits of cellular examination. These innovations yield devices with upgraded features, including better sensitivity, higher parameter detection, and smoother operational workflows, which meet the shifting demands of medical professionals and scientists. Such improvements allow for the precise and thorough profiling of cell groups, a necessity for decoding varied cancer types and intricate immune reactions. For instance, in March 2025, Beckman Coulter Life Sciences introduced the CytoFLEX mosaic Spectral Detection Module, a pioneering modular spectral flow cytometry system providing up to 88 detection channels. These breakthroughs encourage wider utilization by delivering superior data insights and workflow efficiencies. Additionally, robust financial backing demonstrates a strong dedication to advancing research in these fields; in March 2026, The Mark Foundation for Cancer Research raised the total funding of its globally accessible Emerging Leader Award to $1 million per recipient distributed over a four-year period.

Market Challenge

The substantial financial investment required to purchase sophisticated flow cytometry devices and their necessary reagents acts as a major roadblock to the expansion of the global flow cytometry market in oncology and immunology. The preliminary costs for these setups are often massive, covering not just the primary equipment but also essential accessories, setup fees, and continuous maintenance agreements. Consequently, this heavy economic burden creates a steep barrier to entry for numerous prospective users.

These high initial costs directly limit the growth of the market, disproportionately impacting smaller research labs, educational facilities, and healthcare organizations located in developing nations. Because these entities typically function on tighter budgets, obtaining expensive new technologies proves difficult, even with their clear benefits for research and diagnostics. This financial hurdle restricts the broad implementation and regular updating of flow cytometry platforms, consequently hindering overall market penetration. Highlighting this issue, a 2025 TD Securities poll of hospital leaders revealed that 40% of respondents intended to reduce or postpone their investments in capital equipment. This finding illustrates how economic obstacles directly hinder the assimilation of cutting-edge tools such as flow cytometry into everyday clinical and research operations in medical facilities.

Market Trends

A major trend shaping the global flow cytometry market in immunology and oncology is the rising reliance on automated, high-throughput systems, motivated by a demand for greater scalability and productivity in cell analysis. By simplifying intricate procedures and reducing the need for manual input, these systems make it possible to handle significantly larger quantities of samples. This shift toward automation covers everything from preparing samples to gathering data, empowering medical professionals and scientists to speed up their diagnostic and research workflows. To illustrate, an April 2026 report by IntuitionLabs.ai on the 'Dotmatics Platform & AI Integration in Lab Informatics' highlighted a client who processed 42 billion flow cytometry instrument data records in a single year using the Dotmatics Luma platform. This previously unattainable volume underscores the immense data processing power these systems provide, which is essential for extensive screening, pharmaceutical development, and in-depth immune analysis in clinical and laboratory environments.

Concurrently, the incorporation of advanced data analytics and artificial intelligence is revolutionizing the extraction of meaningful information from the intricate datasets produced by flow cytometry. Because these modern instruments generate highly dimensional data, conventional manual evaluation techniques are becoming increasingly inadequate. Machine learning and AI provide advanced resources for discovering biomarkers, identifying cell populations automatically, and spotting anomalies, thereby boosting both the pace and depth of data interpretation. This technological leap enables a more accurate characterization of treatment reactions and disease conditions, advancing the field from simple phenotyping toward predictive analytics. Supporting this shift, October 2025 research from Menlo Ventures showed that 22% of healthcare institutions had adopted domain-specific AI tools. This points to a growing embrace of sophisticated analytical capabilities across the broader healthcare sector, directly impacting how AI is utilized to interpret flow cytometry data for oncology and immunology.

Key Market Players

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Cytek Biosciences, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Enzi Biochem Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA

Report Scope

In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type

• Immunology
• Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology

• Cell-based flow cytometry
• Bead-based Flow Cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering

• Reagents
• Instruments
• Consumables Software

Flow Cytometry in Oncology and Immunology Market, By Application

• Translational Research
• Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User

• Hospitals
• Diagnostic Laboratories and Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

Flow Cytometry in Oncology and Immunology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations:

Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).